Theranica Bio-Electronics Ltd. is a company.
Key people at Theranica Bio-Electronics Ltd..
Theranica Bio-Electronics Ltd. was founded by Shimon Eckhouse (Co-Founder and Chairman of the board).
Theranica Bio-Electronics Ltd. is an Israeli neuromodulation therapeutics company developing non-invasive, drug-free wearable devices for pain management, primarily targeting migraine sufferers.[1][3][6] Its flagship product, Nerivio, is an FDA-cleared prescription remote electrical neuromodulation (REN) wearable applied to the upper arm, controlled via smartphone app, that activates conditioned pain modulation (CPM) to provide acute and preventive relief without drugs, needles, or systemic side effects.[1][5][6] Serving migraine patients including children aged 12+, veterans, those with comorbidities, and women of childbearing age, Nerivio has enabled over one million U.S. treatments and addresses gaps in traditional pharmacotherapy by offering personalized, affordable digital therapeutics.[1][5][7] The company demonstrates strong growth through clinical validation, FDA expansions, and awards like CB Insights' 2020 Game Changer and Fierce Biotech's Medical Innovation Device.[2][4][8]
Founded in 2016, Theranica emerged from a team of experienced professionals leveraging expertise in mobile digital solutions and neuroscience to pioneer pain therapeutics.[2][3] The core idea stemmed from integrating advanced neuromodulation—specifically CPM, where a remote non-painful stimulus triggers brain stem neurotransmitters to inhibit pain—with wireless technology for accessible, at-home use.[3][6] Early traction built on rigorous clinical trials (22 documented) and FDA clearance in 2020 for acute migraine treatment in adults, followed by 2021 expansion to patients 12+ and later preventive indications.[1][4][5] Pivotal moments include Nerivio's rapid adoption, media recognition for reshaping migraine care, and global ambitions from its Israeli base.[4]
Theranica rides the neuromodulation and digital therapeutics wave, shifting pain management from pharmaceuticals to electroceuticals amid rising demand for non-drug options due to opioid crises, side-effect concerns, and migraine prevalence (affecting 1 in 6 people).[1][3][6] Timing aligns with FDA's support for wearables (e.g., 510(k) clearances) and telehealth growth post-pandemic, enabling at-home, personalized care that reduces healthcare burdens.[4][5] Market forces like aging populations, chronic pain epidemics, and Asia expansion (via Pier 88 Health) favor it, while influencing the ecosystem by normalizing CPM-based devices and inspiring drug-free alternatives for idiopathic pain.[1][6]
Theranica is poised to expand Nerivio globally, targeting new indications beyond migraine and partnerships for broader adoption in chronic pain markets.[1][4] Trends like AI-enhanced personalization, wearable integration with health apps, and regulatory tailwinds for digital therapeutics will propel growth, potentially scaling treatments exponentially. Its influence may evolve from migraine pioneer to neuromodulation leader, redefining pain care as proactive and patient-centric—echoing its founding mission to modernize therapeutics without drugs.[3][6]
Theranica Bio-Electronics Ltd. was founded by Shimon Eckhouse (Co-Founder and Chairman of the board).
Key people at Theranica Bio-Electronics Ltd..
